Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has provided an announcement.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has engaged in multiple structured deposit agreements with various banks, including BoCD, CZB, CMB, and ICBC, totaling an outstanding principal amount of RMB1.35 billion. These transactions are considered discloseable under the Listing Rules, indicating a strategic financial maneuver to manage the company’s funds, potentially impacting its liquidity and financial positioning.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company is focused on developing and providing biopharmaceutical products and services.
YTD Price Performance: 58.85%
Average Trading Volume: 360,085
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$57.32B
See more data about 6990 stock on TipRanks’ Stock Analysis page.